BiotechTube
Lifecore Biomedical

Lifecore Biomedical

LFCR
Minneapolis, United States· Est.
lifecore.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

LFCR · Stock Price

USD 4.77+0.75 (+18.66%)
Market Cap: $177.0M

Historical price data

Overview

Lifecore Biomedical is a mission-driven CDMO focused on enabling complex sterile injectable therapeutics. Its key achievement is a 40+ year global regulatory track record, supporting over 20 commercial products from its Midwest facility. The company's core strategy leverages its dual expertise as a full-service CDMO and a proprietary, fermentation-based producer of sodium hyaluronate, creating a differentiated, integrated offering for drug developers in ophthalmology, orthopedics, and dermatology.

OphthalmologyOrthopedicsDermatology

Technology Platform

Integrated platform combining sterile injectable CDMO services with proprietary, fermentation-based manufacturing of pharmaceutical-grade Sodium Hyaluronate (NaHy) across a broad molecular weight spectrum.

Funding History

1
Total raised:$50M
Debt$50M

Opportunities

Growth is driven by increasing outsourcing of complex sterile injectable manufacturing and sustained demand for sodium hyaluronate in aging populations.
Lifecore's unique integrated model allows it to capture value across the entire supply chain, from raw biomaterial to finished drug product.

Risk Factors

Key risks include client concentration, operational/regulatory failures in aseptic processing, intense competition from larger CDMOs pressuring margins, and the inherent volatility of being a micro-cap public stock.

Competitive Landscape

Competes against large, full-service CDMOs and specialized injectable manufacturers on services, and against dedicated NaHy suppliers like Galderma and Contipro on materials. Differentiation lies in technical expertise with complex formulations and the integrated NaHy-CDMO model.

More companies in United States →